Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$27.10 USD
+0.68 (2.57%)
Updated Jul 26, 2024 09:48 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Earnings News For NTLA
-
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
-
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
-
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
-
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
-
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
-
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue Estimates
-
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
-
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
-
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?
-
Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y
-
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
-
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
-
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
-
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
-
Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y
-
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates